As part of its research, Ambiotis announces promising results on a model of IBD and intestinal irritation to evaluate pro-resolving compounds. The model presents a specific metabolipidomic signature that contains immunoresolvent molecules.
This model will thus represent a tool of choice to test compounds that act on intestinal permeability and inflammation and that aim to restore a good intestinal balance thanks to the mobilization of resolutive pathways.